Noninvasive Early Detection and Recurrence Monitoring for Non-Muscle-Invasive Bladder Cancer via Urine Tumor DNA: A...

Area of Science:

• Uro-oncology
• Molecular diagnostics
• Cancer surveillance

Background:

• Conventional non-muscle invasive bladder cancer (NMIBC) detection and surveillance methods are invasive, costly, and burdensome.
• The utLIFE-UC assay identifies urinary tumor DNA, including mutations and copy number variations, showing promise for urothelial carcinoma detection.

Purpose of the Study:

• To evaluate the utLIFE-UC assay's efficacy in the early detection of NMIBC.
• To assess its capability in identifying minimal residual disease post-treatment.
• To determine its utility in monitoring NMIBC recurrence and predicting future relapse.

Main Methods:

• Prospective, longitudinal analysis of urinary tumor DNA using the utLIFE-UC assay in 108 consecutive NMIBC patients.
• Evaluation of assay performance for de novo and recurrent NMIBC detection.
• Correlation of assay results with residual tumor detection after repeat transurethral resection of bladder tumor (Re-TURBT), recurrence-free survival, and clinical recurrence confirmation.

Main Results:

• utLIFE-UC demonstrated 90.5% sensitivity for NMIBC diagnosis, performing comparably for de novo and recurrent cases.
• The assay achieved 100% negative predictive value in identifying residual tumor post-Re-TURBT.
• Positive postoperative results predicted higher relapse risk, and sustained negative results indicated recurrence-free status. Recurrence was predicted with a median lead time of 73.5 days.

Conclusions:

• The utLIFE-UC assay shows significant potential for early NMIBC detection and minimal residual disease identification.
• It can effectively monitor recurrence, predict relapse, and improve risk stratification in NMIBC patients.
• This urinary DNA test may reduce the need for invasive procedures like repeat TURBT and surveillance cystoscopies.